Piramal Pharma Ltd Share Price Today - Piramal Pharma Ltd Stock Price Live NSE/BSE

Piramal Pharma Ltd

NSE: PPLPHARMA BSE: 543635

₹138.35

(1.94%)

Mon, 23 Mar 2026, 03:52 pm

MTF 5xInvest in Piramal Pharma Ltd with 5x Leverage Buy with MTF

Market Cap183.77B

PE Ratio0

Dividend0.10

Health Technology

Pharmaceuticals: Major

24.5K

Piramal Pharma Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
18376.86
Net Profit
91.13
P/B
3.66
Sector P/E
31.86
P/E
325.36
EV/EBITDA
20.63
Debt/Equity (Industry)
0.16
Interest Cover (Industry)
17.01
ROCE (Industry)
16.41
RONW (Industry)
14.52
ROE
1.14
ROCE
6.43
Debt/Equity
0.60
EPS (TTM)
0
Dividend Yield
0.10
Book Value
60.77
Interest Cover
1.98

Analysis

No Result Found

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	34.86	34.86	34.86	34.95	34.95
FII	29.66	30.27	30.86	31.49	31.68
DII	15.69	14.89	14.26	14.78	14.10
Public	19.80	19.98	20.02	18.78	19.27
Government	0.00	0.00	0.00	0.00	0.00

Technical Analysis

RSI

29.49

MACD

-6.55

50 DMA

156.24

200 DMA

184.34

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	198.04	178.26	167.19	158.48	147.41	138.70	118.92
Fibonacci	178.26	170.70	166.03	158.48	150.92	146.25	138.70
Camarilla	161.57	159.76	157.94	158.48	154.32	152.50	150.69

Pivots Level: Classic

+39.56

198.04

+19.78

178.26

+8.72

167.19

158.48

Pivot Point

LTP: 133.27

-11.06

147.41

-19.78

138.70

-39.56

118.92

Moving Average

SMAEMA

Period

Value

10-EMA
141.49
20-EMA
147.05
30-EMA
150.73
50-EMA
156.30
100-EMA
166.77
200-EMA
179.27

Announcement Date	Purpose	Action	Ex Date
28 Jan 2026	board-meetings	Quarterly Results
05 Nov 2025	board-meetings	Quarterly Results, Half Yearly Results
16 Jun 2025	dividend	Final Dividend - Rs. - 0.14	16 Jul 2025
13 Jun 2025	agm
14 May 2025	dividend	₹0.14 Dividend /Share	16 Jul 2025
12 Jun 2024	dividend	Final Dividend - Rs. - 0.11	12 Jul 2024
11 Jun 2024	agm
10 May 2024	dividend	₹0.11 Dividend /Share	12 Jul 2024
27 Jul 2023	rights	5:46 Rights Issue of Equity Shares	02 Aug 2023
02 Jul 2023	rights	Right Issue of Equity Shares	02 Aug 2023

Piramal Pharma Ltd

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd

Divis Laboratories Ltd

Lupin Ltd

Piramal Pharma Ltd About

Piramal Pharma is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network. We operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (“CDMO”) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (“APIs”), Finished dosage forms (“FDFs”), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (“CHG“) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and Piramal Consumer Healthcare (“PCH“) business, selling well-known OTC brands.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

2020

Headquarters

CEO

Nandini Piramal

Employees

Contact

Website

http://www.piramalpharma.com

corporate.secretarial@piramal.com

Phone

91-22-3802-3000/4000

Location

Ground Floor Piramal Ananta, Agastya Corp.Park LBS MargKurl, Mumbai, Maharashtra, 400070

Year	History
2020	The company was incorporated on March 4, 2020 at Mumbai as a public limited company. The company acquired the pharmaceutical business from PEL. The company received a 20% Strategic Growth Investment by Carlyle. The company increased its stake to 100% in CCPL. Piramal Pharma and Navin Fluorine mutually agreed on Piramal increasing its stake to 100% in Convergence Chemicals. Piramal Pharma Solutions collaborated with Epirium Bio on an exclusive integrated development and manufacturing program for orphan drugs. Piramal Pharma Solutions announced an integrated development program with Bolt Biotherapeutics for immune-stimulating antibody conjugates and sterile fill-finish. Piramal Critical Care announced a strategic partnership with US-based pharmaceutical outsourcing facility Medivant Healthcare.
2021	The company acquired HPPL. Piramal Pharma Solutions announced the winner of its Inaugural Award for Excellence in Patient Centricity. Piramal Pharma Solutions entered into a Master Services Agreement with Plus Therapeutics, Inc. Piramal Pharma Limited's Consumer Products Division launched 'i-feel'.
2022	The company acquired a minority stake in Yapan Bio Private Limited. The Composite Scheme of Arrangement was sanctioned by the NCLT on August 12, 2022. Piramal Pharma Solutions announced the winner of its September 2022 Award for Excellence in Patient Centricity. Piramal Pharma Solutions launched ADCelerate, a rapid, integrated approach to taking ADCs to IND. Piramal Pharma Solutions held the grand opening ceremony for its new API plant at Aurora, Canada manufacturing site. Piramal Pharma Solutions' new API plant in Canada went online and initial production runs were successfully completed.
2023	The company issued rights shares of Rs. 10 in the ratio of 5:46 at a premium of Rs. 71 per share.

Client Name	Order Side	QTY	Avg Price	Date
GRAVITON RESEARCH CAPITAL LLP	Sell	6856958	219.88	20 Feb 2025
GRAVITON RESEARCH CAPITAL LLP	Buy	6856958	219.7	20 Feb 2025
EAST BRIDGE CAPITAL MASTER FUND LIMITED	Sell	33643099	102.8	31 Oct 2023
EAST BRIDGE CAPITAL MASTER FUND I LIMITED	Buy	33643099	102.8	31 Oct 2023
THE VANGUARD GROUP INC AC VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND	Buy	6202912	94.71	16 Jun 2023
CAISSE DE DEPOT ET PLACEMENT DU QUEBEC	Sell	10570466	94.48	16 Jun 2023
BLACKROCK ADVISORS LLC A/C THE MASTER TRUST BANK OF JAPAN L	Buy	310097	158.49	01 Nov 2022
BLACKROCK ADVISORS LLC A/C THE MASTER TRUST BANK OF JAPAN L	Sell	14066087	158.88	01 Nov 2022

Piramal Pharma Ltd News

Piramal Pharma Gets ESG Rating of 68.5 for FY25

Piramal Pharma Limited receives an ESG rating of 68.5 from SES ESG Research for FY 2024-25, based on publicly available company data. The rating was assigned voluntarily without company engagement.

20 Mar 2026

companies

Piramal Pharma receives FDA Form-483 with 4 observations

US FDA conducted GMP inspection at Piramal Pharma's Digwal facility from February 9-13, 2026, issuing Form-483 with 4 observations related to procedure enhancements, classified as VAI.

14 Feb 2026

stocks

Piramal Pharma Faces Rs 1 Crore Environmental Penalty

Gujarat Pollution Control Board imposes Rs 1 crore interim environmental damage compensation on Piramal Pharma's Dahej facility following earlier closure directions under Water Act provisions.

11 Feb 2026

stocks

Piramal Pharma Partners for Green Anaesthetic Tech

Piramal Critical Care collaborates with Blue-Zone Technologies to develop waste anaesthetic gas capture and recycling technology, starting in Europe with plans for global expansion.

05 Feb 2026

stocks

Piramal Pharma Independent Director Completes Tenure

Mr. Subramanian Ramadorai completes his 5-year term as Independent Director of Piramal Pharma Limited on February 8, 2026, choosing to retire to pursue personal priorities.

05 Feb 2026

stocks

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800